Financhill
Sell
29

ARMP Quote, Financials, Valuation and Earnings

Last price:
$1.39
Seasonality move :
2.29%
Day range:
$1.36 - $1.70
52-week range:
$0.90 - $3.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
496.58x
P/B ratio:
--
Volume:
10.3K
Avg. volume:
21.2K
1-year change:
-52.1%
Market cap:
$49.6M
Revenue:
--
EPS (TTM):
-$1.32

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARMP
Armata Pharmaceuticals
$1.4M -$0.38 -- -44.93% $7.00
CATX
Perspective Therapeutics
$143.9K -$0.27 -- -35.77% $14.3929
ELMD
Electromed
$15.8M -- 13.91% -- $37.00
INVA
Innoviva
$80.3M $0.41 3.55% -46.05% $19.00
PLX
Protalix BioTherapeutics
$21.6M -- 476.31% -- $14.50
XTNT
Xtant Medical Holdings
$31.2M -$0.01 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARMP
Armata Pharmaceuticals
$1.37 $7.00 $49.6M -- $0.00 0% 496.58x
CATX
Perspective Therapeutics
$2.3500 $14.3929 $174M -- $0.00 0% 15.21x
ELMD
Electromed
$21.99 $37.00 $188.2M 29.32x $0.00 0% 3.30x
INVA
Innoviva
$18.74 $19.00 $1.2B 98.63x $0.00 0% 4.15x
PLX
Protalix BioTherapeutics
$2.84 $14.50 $221.6M 94.67x $0.00 0% 4.41x
XTNT
Xtant Medical Holdings
$0.52 $1.75 $72.1M -- $0.00 0% 0.59x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARMP
Armata Pharmaceuticals
-- 2.116 -- --
CATX
Perspective Therapeutics
-- -1.032 -- --
ELMD
Electromed
-- 2.545 -- 4.68x
INVA
Innoviva
39.35% 0.470 41.24% 2.11x
PLX
Protalix BioTherapeutics
-- 1.057 -- 1.47x
XTNT
Xtant Medical Holdings
44.29% -0.806 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARMP
Armata Pharmaceuticals
-- -$10.5M -- -- -- -$7.9M
CATX
Perspective Therapeutics
-- -$20.9M -- -- -- -$41.2M
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
INVA
Innoviva
$84.6M $43.1M 2.07% 3.44% 32.07% $55.2M
PLX
Protalix BioTherapeutics
$14.3M $7.2M 6.41% 8.75% 40.19% $3.6M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Armata Pharmaceuticals vs. Competitors

  • Which has Higher Returns ARMP or CATX?

    Perspective Therapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of --. Armata Pharmaceuticals's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.23 --
    CATX
    Perspective Therapeutics
    -- -$0.61 --
  • What do Analysts Say About ARMP or CATX?

    Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 410.95%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 512.46%. Given that Perspective Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Perspective Therapeutics is more attractive than Armata Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is ARMP or CATX More Risky?

    Armata Pharmaceuticals has a beta of 0.907, which suggesting that the stock is 9.252% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

  • Which is a Better Dividend Stock ARMP or CATX?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or CATX?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Armata Pharmaceuticals's net income of $2.6M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 496.58x versus 15.21x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    496.58x -- -- $2.6M
    CATX
    Perspective Therapeutics
    15.21x -- -- -$40.2M
  • Which has Higher Returns ARMP or ELMD?

    Electromed has a net margin of -- compared to Armata Pharmaceuticals's net margin of 12.11%. Armata Pharmaceuticals's return on equity of -- beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.23 --
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About ARMP or ELMD?

    Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 410.95%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 68.26%. Given that Armata Pharmaceuticals has higher upside potential than Electromed, analysts believe Armata Pharmaceuticals is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    ELMD
    Electromed
    2 0 0
  • Is ARMP or ELMD More Risky?

    Armata Pharmaceuticals has a beta of 0.907, which suggesting that the stock is 9.252% less volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

  • Which is a Better Dividend Stock ARMP or ELMD?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or ELMD?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Armata Pharmaceuticals's net income of $2.6M is higher than Electromed's net income of $2M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Electromed's PE ratio is 29.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 496.58x versus 3.30x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    496.58x -- -- $2.6M
    ELMD
    Electromed
    3.30x 29.32x $16.3M $2M
  • Which has Higher Returns ARMP or INVA?

    Innoviva has a net margin of -- compared to Armata Pharmaceuticals's net margin of 22.15%. Armata Pharmaceuticals's return on equity of -- beat Innoviva's return on equity of 3.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.23 --
    INVA
    Innoviva
    92.2% $0.26 $1.1B
  • What do Analysts Say About ARMP or INVA?

    Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 410.95%. On the other hand Innoviva has an analysts' consensus of $19.00 which suggests that it could grow by 1.39%. Given that Armata Pharmaceuticals has higher upside potential than Innoviva, analysts believe Armata Pharmaceuticals is more attractive than Innoviva.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    INVA
    Innoviva
    0 1 0
  • Is ARMP or INVA More Risky?

    Armata Pharmaceuticals has a beta of 0.907, which suggesting that the stock is 9.252% less volatile than S&P 500. In comparison Innoviva has a beta of 0.353, suggesting its less volatile than the S&P 500 by 64.673%.

  • Which is a Better Dividend Stock ARMP or INVA?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or INVA?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than Innoviva quarterly revenues of $91.8M. Armata Pharmaceuticals's net income of $2.6M is lower than Innoviva's net income of $20.3M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Innoviva's PE ratio is 98.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 496.58x versus 4.15x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    496.58x -- -- $2.6M
    INVA
    Innoviva
    4.15x 98.63x $91.8M $20.3M
  • Which has Higher Returns ARMP or PLX?

    Protalix BioTherapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of 35.65%. Armata Pharmaceuticals's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.23 --
    PLX
    Protalix BioTherapeutics
    78.67% $0.09 $43.2M
  • What do Analysts Say About ARMP or PLX?

    Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 410.95%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 410.56%. Given that Armata Pharmaceuticals has higher upside potential than Protalix BioTherapeutics, analysts believe Armata Pharmaceuticals is more attractive than Protalix BioTherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is ARMP or PLX More Risky?

    Armata Pharmaceuticals has a beta of 0.907, which suggesting that the stock is 9.252% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

  • Which is a Better Dividend Stock ARMP or PLX?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or PLX?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Armata Pharmaceuticals's net income of $2.6M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 94.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 496.58x versus 4.41x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    496.58x -- -- $2.6M
    PLX
    Protalix BioTherapeutics
    4.41x 94.67x $18.2M $6.5M
  • Which has Higher Returns ARMP or XTNT?

    Xtant Medical Holdings has a net margin of -- compared to Armata Pharmaceuticals's net margin of -10.04%. Armata Pharmaceuticals's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.23 --
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About ARMP or XTNT?

    Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 410.95%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 237.64%. Given that Armata Pharmaceuticals has higher upside potential than Xtant Medical Holdings, analysts believe Armata Pharmaceuticals is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is ARMP or XTNT More Risky?

    Armata Pharmaceuticals has a beta of 0.907, which suggesting that the stock is 9.252% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

  • Which is a Better Dividend Stock ARMP or XTNT?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or XTNT?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Armata Pharmaceuticals's net income of $2.6M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 496.58x versus 0.59x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    496.58x -- -- $2.6M
    XTNT
    Xtant Medical Holdings
    0.59x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Is it Safe to Invest in Google With OpenAI Threats?
Is it Safe to Invest in Google With OpenAI Threats?

For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 8

Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.

Buy
92
TPB alert for May 8

Turning Point Brands [TPB] is down 6.67% over the past day.

Buy
74
LIVN alert for May 8

LivaNova PLC [LIVN] is up 1.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock